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Abstract Patient navigation is emerging as a standard in
breast cancer care delivery, yetmulti-site data on the impact of
navigation at reducing delays along the continuum of care are
lacking. The purpose of this study was to determine the effect
of navigation on reaching diagnostic resolution at specific
time points after an abnormal breast cancer screening test
among a national sample. A prospective meta-analysis esti-
mated the adjusted odds of achieving timely diagnostic reso-
lution at 60, 180, and 365 days. Exploratory analyses were
conducted on the pooled sample to identify which groups had
the most benefit from navigation. Clinics from six medical
centers serving vulnerable populations participated in the
Patient Navigation Research Program. Women with an
abnormal breast cancer screening test between 2007 and 2009
were included and received the patient navigation intervention
orusual care. Patient navigatorsworkedwith patients and their
care providers to address patient-specific barriers to care to
prevent delays in diagnosis. A total of 4675 participants
included predominantly racial/ethnic minorities (74 %) with
public insurance (40 %) or no insurance (31 %). At 60 days
and 180 days, there was no statistically significant effect of
navigation on achieving timely diagnostic care, but a benefit
of navigation was seen at 365 days (aOR 2.12, CI 1.36–3.29).
We found an equal benefit of navigation across all groups,
regardless of race/ethnicity, language, insurance status, and
type of screening abnormality. Patient navigation resulted in
more timely diagnostic resolution at 365 days among a
diverse group of minority, low-income women with breast
cancer screening abnormalities.
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Introduction
Inequities in breast cancer mortality persist, with recent
evidence suggesting that they are worsening for certain
vulnerable populations [1–4]. Delays in delivering timely
breast cancer care lead to more advanced stage at diagnosis
and ultimately more breast cancer deaths for low-income
minority communities [3–7]. While the interplay of race,
poverty, and other socioeconomic indicators on cancer
outcomes is complex, the literature clearly documents the
impact that barriers to accessing cancer care has on these
patient’s outcomes [7–10]. The presence of patient-identi-
fied barriers to health care leads to delays in care and is
increasingly scrutinized as a source of poor survival for
many vulnerable populations [2, 4–6, 11–16], while large
population-based studies report that equal high-quality
treatment can significantly reduce disparities in mortality
[2–17].
Patient navigation represents a promising practice to
reduce disparities in cancer care delivery by intervening to
address barriers to timely care. Navigation is a patient-
centered care coordination model that deploys health
workers integrated into the healthcare team to target dis-
advantaged patients for a defined episode of care [18–20].
The specific goal of navigation is to reduce delays in care
by identifying and addressing patient-identified barriers to
care. Early studies documented the benefits of patient
navigation along the breast cancer care continuum,
including improvements in mammography screening rates,
and reductions in diagnostic delays following abnormal
screening tests or treatment initiation [20, 21]. Despite the
evidence limitations, including studies with small sample
sizes, single-site studies, a lack of valid comparison groups,
and the use of disparate outcome metrics that preclude
comparison, rapid dissemination of the patient navigation
model resulted in the American College of Surgeons
(ACoS) Commission on Cancer including patient naviga-
tion as an accreditation standard [22] and provisions of the
Affordable Care Act specifying patient navigation as a
means to address barriers to health services [23].
Implementation of this healthcare delivery model into
everyday cancer care practice requires evidence that
informs best practice. Thus, there is a critical need for
generalizable data that provide evidence which is useful in
practice. With limited healthcare resources, it is imperative
to understand where in the breast cancer care continuum
patient navigation has the greatest impact, and on which
populations. Using data from a national multicenter clinical
trial, we aim to examine the impact of patient navigation on
reaching diagnostic resolution at specific time points after
an abnormal breast cancer screening test and explore which
groups of vulnerable patients have the greatest benefit in an




We conducted a secondary analysis of data from the
National Patient Navigation Research Program (PNRP),
the first multicenter clinical trial to examine the benefits of
patient navigation among underserved populations with
screening abnormalities suspicious for cancer [24]. We
conducted a prospective, random-effects meta-analysis
based on data from individual patients to determine the
effect of navigation on the likelihood of resolution at three
specific time points after the screening abnormality was
detected, 60, 180 and 365 days.
We chose a prospective meta-analysis design to aug-
ment the findings being reported by the individual centers
in the PNRP multi-site investigation [17, 24–29]. A meta-
analysis contributes to our understanding of the potential
benefits of navigation beyond the center-specific findings
because it has the distinct advantage of simultaneously and
deliberately considering the individual study results in
relation to the parent study and makes transparent the
differences and similarities in outcomes observed across
the participating study centers. A framework that allows for
joint attention to similarities and differences in outcomes
across study centers can illuminate what is working across
varied settings as well as prompt ideas for hypothesis
testing in future studies.
Our prospective meta-analysis overcomes some of the
limitations of a more traditional retrospective meta-analy-
sis of published studies in that our sample of studies,
though small, was not vulnerable to publication bias or
search bias. Furthermore, by selecting studies that are part
of a larger, multicenter study, we are choosing only studies
that are uniform in both the design and implementation of
the intervention and in how the outcomes were measured,
thereby reducing important sources of potential hetero-
geneity. We acknowledge that we combined studies of
varying research designs, but there are no technical
grounds necessitating the removal of non-randomized,
controlled designs from a meta-analysis. At the same time,
the dissimilarities in patient and institutional characteristics
524 Breast Cancer Res Treat (2016) 158:523–534
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as well as geographic region strengthen the generalizability
of our findings [30]. Our prospective design also gave us
access to individual, patient-level data which meant that we
were not limited by having only summary statistics to
perform our analyses. In addition to the meta-analysis, we
pooled data from each site in an effort to try to identify the
characteristics of the populations that benefited most from
the intervention.
Settings and participants
Initially, 10 PNRP centers recruited participants from local
community health centers or ambulatory care sites, caring
primarily for low-income, uninsured, or publically insured
populations [24]. In our analysis, we excluded four centers:
one did not enroll breast participants [29], one enrolled too
few breast participants to conduct meaningful center-level
analyses [28], one did not offer a comparison group
amenable to our outcome analysis [31], and one focused on
Native American/Alaskan Native communities whose data
sharing agreements precluded inclusion in the combined
dataset [27]. Eligible participants from the six centers were
women 18 years of age or older enrolled with any of the
following breast cancer screening abnormality: mammo-
grams, ultrasound, or magnetic resonance imaging (MRI)
of the breasts coded by the Breast Imaging Reporting and
Data System [32] (BI-RADS) as a 0, 3, 4, or 5 as well as
abnormal clinical breast examinations with a mass or other
lesion suspicious for cancer (n = 4738). For this analysis,
PNRP participants were excluded if they had missing eli-
gibility information (n = 1), if they had a concurrent cer-
vical cancer screening abnormality (n = 14), or because
they were no longer able to participate in the study (e.g.,
deceased, moved out of the country, transferred care to
another facility (n = 58). See Fig. 1.
Randomization and interventions
Each of the six centers contributing to this analysis designed
study methods in the context of the community setting in
which it operated. One center conducted an individually
randomized clinical trial [29] requiring written informed
consent, two centers conducted a group-randomized trial
[20, 28], and three centers used quasi-experimental designs
with nonrandomassignment into the intervention and control
arms at the group level [17, 27, 31]. The institutional review
board for each respective center approved the research.
The patient navigation intervention was modeled after
the principles of care coordination [33]. All navigators
across the study sites participated in shared face-to-face
national trainings held annually and in periodic webinars to
ensure standardization across centers [34]. The research
team conducted annual core competency assessments on all
navigators and provided feedback to local supervisors.
Navigation was initiated after a clinician informed the
participant of the abnormal test result. Navigators first
identified those in need of navigation services, then iden-
tified participant-level barriers to recommended care, and
developed strategies to address these barriers, with the
focus on timely completion of diagnostic evaluation.
Navigators were imbedded within clinical care systems
with close interface with the clinical practice, and patient
follow-up occurred by telephone, mail, and in face-to-face
meetings [27, 28, 31, 33–35].
Outcomes and follow-up
All study variable definitions were developed by the PNRP
Design and Analysis Committee and implemented uni-
formly at all centers [24]. Clinical variables were obtained
from participants’ medical records, including type of
screening abnormality, dates and types of diagnostic test
category, and clinical outcomes. Demographics were
obtained from either patient self-report or medical record
registration.
Dependent variable
Themain outcomemeasure was timely diagnostic resolution
of the identified breast abnormality, measured at three
specified time points: 60, 180, and 365 days.We chose these
endpoints based on their clinical relevance, as reflected in
their use as quality metrics by the American Society of
Clinical Oncology/National Comprehensive Care Network
Quality Measures and the ACoS Commission on Cancer
[35], their known effect on survival [4, 36], use for com-
parison with other studies [37], and practical relevance to
implementation. Diagnostic resolution was defined as
receipt of a definitive diagnosis (malignant or benign) either
through a cytologic or pathologic tissue sample, or through a
breast imaging or clinical evaluation that determined no
further tests were recommended. For BI-RADS 3 imaging,
where short-term imaging is recommended, we tracked
participants only through the next recommended imaging.
The number of days to resolutionwas calculated based on the
elapsed time between the recorded date of the initial abnor-
mal cancer screening test result and the date of diagnostic
resolution. To establish a comparable baseline for BI-RADS
3 cases, where 180 days is themost frequently recommended
follow-up period, we subtracted 180 days from the total
number of days. For those where resolution was obtained in
fewer than 180 days, we assigned them to 0 days to prevent
unnatural event times (negative durations). The number of
days was used to generate the binary outcome of diagnostic
resolution (coded yes/no) for each time period 60, 180, and
365 days.
Breast Cancer Res Treat (2016) 158:523–534 525
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Independent variable
The main independent variable of interest is whether a
patient was in the navigation or control group.
Covariates
A common set of variables collected identically across
each study center was included as covariates: age (in
years); race/ethnicity (White, African American, Hispanic,
or other/unknown); primary language (English or other/
unknown); health insurance status (private insurance,
public insurance, no insurance); and type of screening
abnormality (clinical breast examination, BI-RADS 0/un-
known, BI-RADS 3, BI-RADS 4/5).
Statistical analysis
We use descriptive statistics to report socio-demographic
characteristics of participants and t tests and Chi-square to
compare them by enrollment status (navigated vs. control).
For the meta-analysis, we used a two-step approach. First,
we analyzed each center independently using a multivari-
able logistic regression model for each of the specified time
points (60, 180, and 365 days). All models were adjusted
for a subject’s race/ethnicity, primary language, insurance
status, age, and type of cancer screening abnormality. This
step produced a mean treatment effect estimate and its
standard error for each center. Secondly, we performed a
random-effects meta-analysis in order to generate an
overall treatment effect for each specified time point (60,





Excluded 1 center: did not 
enroll breast parcipants25
All PNRP Parcipants Assessed for Eligibility
(6 study centers)
(n=4,748 parcipants)
Excluded for cervical 
cancer
(n=14 parcipants)
Excluded for changing 
providers
(n=58 parcipants)
Excluded for missing 
eligibility 
(n=1 parcipants)
Excluded 1 center: 
enrolled too few breast 
parcipants26
Excluded 1 center: did not 
offer comparison group 
amenable to outcome 
analysis27
Excluded 1 center: Nave 
American communies whose 
data sharing agreements 
precluded inclusion in a 
combined dataset28
Fig. 1 CONSORT diagram for selection of study centers and participants
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180, and 365 days). We fit a random-effects model to
acknowledge that the effects being estimated were not
identical across centers [38] since we anticipated hetero-
geneity among the centers [26], and a random-effects
model reduces the weights of individual studies, thus
minimizing the likelihood that any obtained significant
overall effect is a function of a single center. We further
investigated the influence of each study on the overall
estimate by omitting one study at a time in a sensitivity
analysis. Note that in the rare instances where data about a
covariate were missing among the 4675 subjects (i.e.,
n = 10 for BI-RADS; n = 14 for age; n = 18 for primary
language; n = 33 for insurance status; and n = 44 for race/
ethnicity), we simply collapsed the missing cases into the
‘‘Other’’ categories since the amount of missing data was
negligible.
To explore characteristics of participants who benefited
most from the navigation intervention, we then pooled data
from all sites. First, we simply compared rates of resolution
at each of the three time points for both intervention and
control participants. Then, we looked specifically at the
subset of participants who had not yet achieved diagnostic
resolution by 180 days, as a means to isolate the period
demonstrating a benefit of navigation. Data management
and statistical calculations were performed with Stata
software (version 11.2-SE; Stata Corporation, College
Station, TX).
Results
Table 1 displays the demographic characteristics of the
4675 participants and enrollment across all centers. The
mean age of women was 48.7 years [standard deviation
(SD) 12.1 years], and most were non-White and either
uninsured or had publicly funded health coverage. The
majority were enrolled based on an abnormal finding on a
screening mammogram vs a clinical breast examination
finding. Compared with controls, navigated participants
were more likely to be younger, Hispanic or other race/
ethnicity, be uninsured, and have an abnormal clinical
breast examination as their eligibility criteria.
Table 1 Demographics of
participants with an abnormal
breast cancer screening test
enrolled in the Patient
Navigation Research Program






N (%) N (%) N (%)
Age (mean, SD) n = 4675 48.7 (11.9) 47.1 (12.1) 50.1 (11.5) p = 0.000
Race/ethnicity n = 4675 p = 0.000
White 1470 (31.4) 749 (33.4) 721 (29.6)
Black 913 (19.5) 310 (13.8) 603 (24.8)
Hispanic 2039 (43.6) 1021 (45.6) 1018 (41.8)
Other 253 (5.4) 161 (7.2) 92 (3.8)
Language n = 4675 p = 0.171
English 2789 (59.7) 1314 (58.6) 1475 (60.6)
Other 1886 (40.3) 927 (41.4) 959 (39.4)
Insurance status n = 4648 n = 2227 n = 2421 p = 0.000
Private 1168 (25.1) 544 (24.4) 624 (25.8)
Uninsured/other 1637 (35.2) 848 (38.1) 789 (32.6)
Public 1843 (39.7) 835 (37.5) 1008 (41.6)
Type of screening abnormality n = 4675 p = 0.000
Abnormal breast exam 1284 (27.5) 809 (36.1) 475 (19.5)
BI-RADS 0/other 2558 (54.7) 1042 (46.5) 1516 (62.3)
BI-RADS 3 646 (13.8) 292 (13.0) 354 (14.5)
BI-RADS 4/5 187 (4.0) 98 (4.4) 89 (3.7)
PNRP Site n = 4675 p = 0.000
A 1712 (36.6) 749 (33.4) 963 (39.6)
B 352 (7.5) 147 (6.6) 205 (8.4)
D 634 (13.6) 312 (13.9) 322 (13.2)
E 475 (10.2) 282 (12.6) 193 (7.9)
F 448 (9.6) 251 (11.2) 197 (8.1)
G 1054 (22.6) 500 (22.3) 554 (22.8)
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Figures 2, 3, and 4 use forest plots to report the meta-
analysis of the adjusted odds ratios (aORs) for timely
diagnostic resolution at 60, 180, and 365 days, respec-
tively, where adjusted odds greater than one indicate a
benefit in the navigated arm. At 60 days and 180 days of
care, there was no statistically significant effect of navi-
gation on achieving timely diagnostic care, but a statisti-
cally significant benefit of navigation was seen at 365 days.
At 60 days, the aOR for achieving diagnostic resolution
was 1.01 [95 % confidence interval (CI) 0.84, 1.22]. At
180 days, the aOR for achieving diagnostic resolution was
1.37 (95 % CI 0.99, 1.88). At 365 days, the aOR for
achieving diagnostic resolution was 2.12 (95 % CI 1.36,
3.29), indicating a statistically significant benefit in the
navigated arm. There was significant heterogeneity among
the centers (I2 = 69.0 %, p = 0.006).
While our pooled effect size did not show an overall
benefit of navigation at 60 days or 180 days, several sites
did demonstrate benefit at these specified time frames. For
example, site B had an aOR of 1.98 (95 % CI 1.05, 3.73) at
60 days, aOR of 3.17 (95 % CI 1.36, 7.39) at 180 days, and
aOR of 8.63 (95 % CI 1.87, 39.80) at 365 days. Similar
results are seen for sites C and F. Further, the direction of
the association was consistent with an increasing benefit of
navigation over time. Influence analyses, which systemat-
ically omitted each of the six centers, always produced an
effect size within the confidence interval of the original
calculation.
To explore factors associated with diagnostic resolution
of a breast cancer screening abnormality at 365 days, we
display results from each individual study center logistic
regression models (Table 2). We did not find race/ethnic-
ity, language, insurance status, or type of screening
abnormality to be independently associated with timely
diagnostic resolution at 365 days.
We pooled data across all six centers to explore char-
acteristics of the participants who benefited most from the
navigation intervention. At 60 days, a little more than half
of all enrolled participants achieved diagnostic resolution
(58 % in the intervention arm and 56 % in the control
arm). At 180 days, almost three quarters of each group
achieved diagnostic resolution (76 % intervention arm
versus 70 % control arm). At 365 days, 92 % of the nav-
igated participants achieved diagnostic resolution com-
pared with only 84 % of the control participants achieving
diagnostic resolution.
Figure 5 displays the results of our pooled data analyses,
looking specifically at the participants who benefited from
Fig. 2 Meta-analysis of impact of patient navigation on diagnostic resolution 60 days after breast cancer screening abnormality: Patient
Navigation Research Program
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the intervention, which includes the 1252 participants who
had not yet achieved diagnostic resolution by 180 days.
Figure 4 compares the percent of PNRP intervention and
control participants achieving diagnostic resolution between
180 and 365 days across each demographic and clinical
group. Overall, only 45 % of those in the control group
achieved diagnostic resolution by 365 days, compared with
64 % of intervention participants. With the exception of
participants enrolled with a BI-RADS 4/5 screening test
(n = 41), each group demonstrated a benefit of navigation.
For example, among patients within the control group, 42 %
of non-English speakers reached diagnostic resolution after
180 days (by 365 days); by contrast, among patients within
navigated group, 66 % of non-English speakers reached
diagnostic resolution (Fig. 5).
Discussion
This is the first meta-analysis performed to examine the
association between patient navigation and diagnostic res-
olution at specified time points after an abnormal breast
cancer screening test. Among a diverse population of vul-
nerable women, benefits of the navigation intervention were
suggested only among the group that had not yet achieved
resolution by 180 days, yet this impact was seen for all
demographic groups. Our data suggest that navigation has
the greatest impact on cancer care delivery among the group
who would otherwise be lost to follow-up after one year.
These findings provide practical implications for programs
seeking guidance on how to best implement navigation into
everyday practice. Should navigation be implemented as a
means to specifically address disparities in cancer out-
comes, this study suggests that navigation resources be
targeted to those with persistent delays in care.
Study methods are notable for several advantages,
compared to existing navigation studies which are limited
by single-site studies [20, 25, 37, 39–47]. First, we targeted
a racial/ethnically diverse population of vulnerable patients
seeking care in safety net settings across the country.
Furthermore, our prospective meta-analysis utilized indi-
vidual participant data [48]. Advantages of this approach
include overcoming common limitations of traditional
meta-analysis in publication bias and within-study selec-
tive reporting. It also allowed us to standardize the analyses
(same covariates) across studies.
The lack of demonstrated benefit prior to 365 days may
be explained by the ability of participants to overcome
obstacles to diagnostic care in the absence of a navigator
perhaps due to the presence of existing systems within the
Fig. 3 Meta-analysis of Impact of Patient Navigation on Diagnostic Resolution 180 Days after Breast Cancer Screening Abnormality: Patient
Navigation Research Program
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healthcare setting that increase the likelihood that women
will obtain resolution. We found over half of study par-
ticipants, regardless of navigation status, achieved diag-
nostic resolution by 60 days. Perhaps these women have
barriers to care that usual care is already adept at
addressing. There are emerging data to suggest that certain
barriers to care, such as housing, disability or employment
issues, are more common among those who initially delay
care [49]. Since we did not collect information on barriers
in control participants, we are unable to account for them in
these analyses. Another possible consideration is that the
group with initial delays require more complex or multi-
step diagnostic services to achieve resolution and thus had
more opportunity for navigators to provide necessary
support services. The PNRP dataset only included infor-
mation on the final diagnostic test, without accounting for
the multiple other clinical, radiographic, or pathologic tests
that might have preceded a final diagnosis. Finally, a
possible explanation of the lack of a benefit prior to
365 days is delay in the delivery of navigation services.
This is unlikely, however, as our enrollment data show that
most women (87 %) were enrolled with documentation of
navigation interaction by 60 days.
While our pooled effect size demonstrated no overall
benefit of navigation at 60 or 180 days, it is important to
recognize that several sites did demonstrate benefit at these
specified time points. This suggests the presence of
unmeasured center-specific differences, at either the level
of the patient or health system. For example, the presence
of specific barriers to care for participants at these sites
may differ from barriers at sites without demonstrated
benefit at those earlier time frames. Or perhaps the baseline
delays in care were greater for the sites with demonstrated
benefit at earlier time frames. Or on the contrary, sites
without demonstrated benefit may have had unmeasured
system level resources that provided navigation-like ser-
vices. Understanding these site-level differences is critical
in order to disseminate navigation services in the most
efficient manner.
Our study demonstrated an association of navigation
and timely care specifically among those whose care was
not resolved by 180 days, and the benefit was equal
across each demographic group. This is important in
relation to disparities in breast cancer, because we know
that delays from onset of symptoms to first treatment are
associated with shorter survival [4, 50]. Our findings
have implications for practices across the country in the
process of transforming their care delivery systems to
achieve expectations set by the Affordable Care Act for
improving quality and efficiency of health care [23], as
Fig. 4 Meta-analysis of impact of patient navigation on diagnostic resolution 365 days after breast cancer screening abnormality: Patient
Navigation Research Program
530 Breast Cancer Res Treat (2016) 158:523–534
123
the current evidence for implementing care coordination
best practices is lacking [51]. Our multicenter study
findings suggest that care coordination programs targeting
timely breast cancer diagnosis should consider specifi-
cally targeting patient navigation resources to those with
initial delays in care, regardless of socio-demographics.
Until evidence from multicenter implementation studies
are available, studies such as ours are important to
inform the translation of existing evidence into everyday
practice.
There are limitations to this study. The heterogeneity we
observed across centers in the meta-analysis reflects the
reality of community-engaged research, which introduces
limitations to conduct pooled analyses but increases gen-
eralizability. Given differences in contextual factors among
the centers and the nature of the navigation intervention,
there are likely individualized implementation differences
across centers that were not measured. In the presence of
heterogeneity, we fit a random-effects meta-analysis. We
also attempted to explore the causes of heterogeneity. One
Table 2 Adjusted odds of achieving diagnostic resolution at 365 days for each PNRP study center
Characteristic PNRP study center








































































































































Bold indicates statistical significance P\ 0.05
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potential cause is the methodological diversity of the
centers [31], but the six centers examined here are too few
to further divide into subgroups by type of study design and
then conduct the meta-analysis. Another potential cause of
the heterogeneity is site B/C, which has a wide confidence
interval around its large effect size. We are reassured in our
sensitivity analysis that when we omit the site showing the
largest positive benefit of navigation, site B/C, the com-
bined effect remains positive. We have further confidence
in the pooled effects from the forest plot at 365 days,
which reveal that all of the estimated effects fall on the
same side of the unit line, although in three cases the effect
was not statistically significant. Moreover, the odds ratios
across all six studies are positive, regardless of study
design, and thus suggest a consistency in the effect. For
these reasons, we have confidence in our average inter-
vention effect.
In conclusion, this study provides the first multicenter
evidence to specify where in the diagnostic care spectrum
that patient navigation may have a role in addressing out-
come disparities. These data suggest that if we target
navigation services to those with persistent delays in breast
cancer diagnosis, regardless of socio-demographics, we can
improve the quality of care delivery that is necessary to
ensure equity in breast cancer survival.
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Fig. 5 Proportion of participants with abnormal breast cancer screening who completed diagnostic evaluation between 180 and 365 days: the
Patient Navigation Research Program. N = 1252
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